Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Beta-thalassemia and beta thalassemia-hemoglobin E (HbE), as confirmed by DNA testing~* Transfusion independent for at least 120 days before study entry~* Red blood cell folate levels above the lower limit of normal~Exclusion Criteria:~* Absolute neutrophil count (ANC) less than 2000/mm3 in the 8 weeks before study entry or a history of chronic neutropenia, defined as an ANC less than 2000/mm3~* Platelet count less than 100,000/mm3 or greater than 1,000,000/mm3 in the 8 weeks before study entry~* Family history of an inherited disease resulting in low ANC or bone marrow failure~* Serum creatinine level greater than 2 mg/dL in the 8 weeks before study entry~* Evidence of liver disease, as defined by one or more of the following conditions:~  1. Alanine aminotransferase (ALT) level greater than 3 times the upper limit of normal in the 8 weeks before study entry~ 2. Serum albumin level less than 3 g/dL in the 8 weeks before study entry~ 3. Evidence of cirrhosis on liver biopsy obtained in the 6 months before study entry~* Approaching death; has concurrent liver, kidney, cardiac, or metabolic disease; or has any disease of such severity that death within 7 to 10 days of study entry is likely~* Pregnant, planning to become pregnant, or breastfeeding~* Sexually active female of childbearing potential who is unwilling to use at least two acceptable methods of contraception, as determined by the investigator~* Sexually active male whose partner is of child-bearing potential and who is unwilling to use at least two acceptable methods of contraception, as determined by the investigator, during and for 2 months after decitabine treatment~* Diagnosed with cancer (except non-melanoma skin cancer) in the 5 years before study entry. In particular, suspicion or evidence of myelodysplastic syndrome (MDS) on clinically indicated bone marrow aspirate or a family history of MDS or concurrent leukemia~* HIV infection~* Not expected to be able to complete 24 weeks of study follow-up~* Currently being treated with any experimental or fetal hemoglobin modulating agent~* Current participation in any other studies of investigational drugs or devices~* Unable to comply with study medication regimen~* Any condition, which in the opinion of the investigator, would place the individual at undue risk if treated with twice-weekly low-dose decitabine for 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive injected decitabine for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).